Advertisement

Advertisement

ARMP Stock Latest News

Analyst Reiterates Buy on Armata, Maintaining $20 Price Target Ahead of Pivotal Phase 3 AP-SA02 Trial

RatingsAnalyst Reiterates Buy on Armata, Maintaining $20 Price Target Ahead of Pivotal Phase 3 AP-SA02 Trial

Armata Secures New Loan Amid Wider Quarterly Loss

PremiumCompany Announcements

Armata Secures New Loan Amid Wider Quarterly Loss

18d ago

Armata Pharmaceuticals reports Q1 EPS ($3.16) vs. (20c) last year

PremiumThe Fly

Armata Pharmaceuticals reports Q1 EPS ($3.16) vs. (20c) last year

18d ago

Armata Pharmaceuticals secures FDA Fast Track Designation for AP-SA02

PremiumThe Fly

Armata Pharmaceuticals secures FDA Fast Track Designation for AP-SA02

25d ago

Armata Gains FDA Fast Track for AP-SA02 Therapy

PremiumCompany Announcements

Armata Gains FDA Fast Track for AP-SA02 Therapy

25d ago

Armata Pharmaceuticals Adds Pfizer Executive to Board of Directors

PremiumCompany AnnouncementsArmata Pharmaceuticals Adds Pfizer Executive to Board of Directors

1M ago

Armata Pharmaceuticals price target raised to $20 from $15 at JonesResearch

The Fly

Armata Pharmaceuticals price target raised to $20 from $15 at JonesResearch

2M ago

Armata Pharmaceuticals Sets Timeline for 2026 Annual Meeting

Company Announcements

Armata Pharmaceuticals Sets Timeline for 2026 Annual Meeting

2M ago

Armata Pharmaceuticals reports Q4 EPS ($3.42) vs. (23c) last year

PremiumThe Fly

Armata Pharmaceuticals reports Q4 EPS ($3.42) vs. (23c) last year

2M ago

Armata Highlights AP-SA02 Progress Amid Earnings Release Delay

PremiumCompany Announcements

Armata Highlights AP-SA02 Progress Amid Earnings Release Delay

2M ago

Armata Pharmaceuticals delays announcement of Q4, FY25 results

PremiumThe Fly

Armata Pharmaceuticals delays announcement of Q4, FY25 results

2M ago

ARMP Earnings Report this Week: Is It a Buy, Ahead of Earnings?

PremiumPre-Earnings

ARMP Earnings Report this Week: Is It a Buy, Ahead of Earnings?

3M ago

Armata price target raised to $15 from $9 at H.C. Wainwright

PremiumThe FlyArmata price target raised to $15 from $9 at H.C. Wainwright

3M ago

Armata Gains QIDP Status for AP-SA02 Bacteremia Therapy

Company Announcements

Armata Gains QIDP Status for AP-SA02 Bacteremia Therapy

3M ago

Armata Pharmaceuticals receives FDA QIDP designation for AP-SA02

The Fly

Armata Pharmaceuticals receives FDA QIDP designation for AP-SA02

3M ago

Armata Extends Innoviva Credit, Warrants and Voting Pact

PremiumCompany Announcements

Armata Extends Innoviva Credit, Warrants and Voting Pact

4M ago

Armata Pharmaceuticals: FDA-Endorsed Phase 3 Path and Potential QIDP Upside Support Buy Rating on AP-SA02

PremiumRatings

Armata Pharmaceuticals: FDA-Endorsed Phase 3 Path and Potential QIDP Upside Support Buy Rating on AP-SA02

5M ago

Armata Wins FDA Support to Advance Bacteriophage to Phase 3

PremiumCompany Announcements

Armata Wins FDA Support to Advance Bacteriophage to Phase 3

5M ago

Armata Pharmaceuticals announces End-of-Phase 2 meeting with FDA

PremiumThe Fly

Armata Pharmaceuticals announces End-of-Phase 2 meeting with FDA

5M ago

Armata Pharmaceuticals initiated with a Buy at JonesResearch

PremiumThe FlyArmata Pharmaceuticals initiated with a Buy at JonesResearch

5M ago

Armata Pharmaceuticals Enters Capital Sales Agreement

Company Announcements

Armata Pharmaceuticals Enters Capital Sales Agreement

6M ago

Armata Pharmaceuticals: Strategic Advancements and Clinical Progress Drive Buy Rating

Ratings

Armata Pharmaceuticals: Strategic Advancements and Clinical Progress Drive Buy Rating

7M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >